{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-232621","form_type":"8-K","ticker":"CNMD","cik":"0000816956","company_name":"CONMED Corp","filed_at":"2024-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.091215+00:00","generated_at":"2026-05-30T21:00:17.438283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CONMED prelim Q3 rev $315-318M; adj EPS growth to exceed 9-11% guide","bullets":["Revenue expected $315M-$318M for Q3 2024 (preliminary).","Adjusted diluted EPS growth exceeds previously guided 9%-11% range.","Full Q3 results to be reported Oct 30, 2024 after market close.","Data is preliminary; may change upon completion of financial close."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-232621","json":"https://secwatch.observer/filing/0001193125-24-232621.json","markdown":"https://secwatch.observer/filing/0001193125-24-232621.md","text":"https://secwatch.observer/filing/0001193125-24-232621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/816956/000119312524232621/0001193125-24-232621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/816956/000119312524232621/d117527d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:00:17.438283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}